Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/25876
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVenneri, A-
dc.contributor.authorDe Marco, M-
dc.date.accessioned2023-01-26T14:14:26Z-
dc.date.available2023-01-26T14:14:26Z-
dc.date.issued2020-10-30-
dc.identifierORCID iDs: Annalena Venneri https://orcid.org/0000-0002-9488-2301; Matteo De Marco https://orcid.org/0000-0002-9240-8067.-
dc.identifier18707-
dc.identifier.citationVenneri, A. and De Marco, R. (2020) 'Reduced monoaminergic nuclei MRI signal detectable in pre-symptomatic older adults with future memory decline', Scientific Reports, 10 (1), 18707, pp. 1 - 11. doi: 10.1038/s41598-020-71368-1.en_US
dc.identifier.issn18707-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/25876-
dc.descriptionSupplementary information: Supplementary file1 (Microsft Word docx) available at https://static-content.springer.com/esm/art%3A10.1038%2Fs41598-020-71368-1/MediaObjects/41598_2020_71368_MOESM1_ESM.docxen_US
dc.description.abstractCopyright © The Author(s) 2020. Evidence from murine models and human post-mortem studies indicates that monoaminergic nuclei undergo degeneration at the pre-symptomatic stage of Alzheimer's disease (AD). Analysing 129 datasets from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and relying on the Clinical Dementia Rating as group-defining instrument, we hypothesised that the MRI signal of monoaminergic nuclei would be a statistically significant predictor of memory decline in participants initially recruited in ADNI as healthy adults. As opposed to a group of cognitively stable participants, participants developing memory decline had reduced signal in the ventral tegmental area at baseline, before any evidence of functional decline emerged. These findings indicate that monoaminergic degeneration predates the onset of memory decline in an AD-centred initiative, with a crucial involvement of very-early changes of a dopaminergic region. This translates into potential informative avenues for pharmacological treatment of pre-symptomatic AD.en_US
dc.description.sponsorshipThis manuscript is not associated with any sources of funding.en_US
dc.format.extent1 - 11-
dc.format.mediumElectronic-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherSpringer Natureen_US
dc.rightsCopyright © The Author(s) 2020. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectmedical researchen_US
dc.subjectneurologyen_US
dc.subjectneuroscienceen_US
dc.subjectpsychologyen_US
dc.titleReduced monoaminergic nuclei MRI signal detectable in pre-symptomatic older adults with future memory declineen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1038/s41598-020-71368-1-
dc.relation.isPartOfScientific Reports-
pubs.issue1-
pubs.notesVenneri, Annalena De Marco, Matteo eng U01 AG024904/AG/NIA NIH HHS/ CIHR/Canada Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural England 2020/11/01 06:00 Sci Rep. 2020 Oct 30;10(1):18707. doi: 10.1038/s41598-020-71368-1. Evidence from murine models and human post-mortem studies indicates that monoaminergic nuclei undergo degeneration at the pre-symptomatic stage of Alzheimer's disease (AD). Analysing 129 datasets from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and relying on the Clinical Dementia Rating as group-defining instrument, we hypothesised that the MRI signal of monoaminergic nuclei would be a statistically significant predictor of memory decline in participants initially recruited in ADNI as healthy adults. As opposed to a group of cognitively stable participants, participants developing memory decline had reduced signal in the ventral tegmental area at baseline, before any evidence of functional decline emerged. These findings indicate that monoaminergic degeneration predates the onset of memory decline in an AD-centred initiative, with a crucial involvement of very-early changes of a dopaminergic region. This translates into potential informative avenues for pharmacological treatment of pre-symptomatic AD.-
pubs.publication-statusPublished-
pubs.volume10-
dc.identifier.eissn2045-2322-
dc.rights.holderThe Author(s)-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2020. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.3.31 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons